• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
SNDX

SNDX

Syndax Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD18.39

-0.46 (-2.44%)

Rating:D+

Company Profile

CEO

Michael A. Metzger

IPO Date

2016-03-02

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$18.67

Prev. Close

$18.85

Day Low

$18.20

Day High

$19.00

52W Low

$8.59

52W High

$25.59

Market Cap

$1.63B

Volume

1.34M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

46.8%

Avg Negative

2.9%

Avg Neutral

50.3%

News Feed

SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias

PRNewsWire·6/28/2021·↑ positive

Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference

PRNewsWire·6/3/2021·↑ positive

Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit

PRNewsWire
·5/13/2021
·↑ positive

Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial

Benzinga·5/12/2021·↑ positive

Syndax Pharmaceuticals, Inc. (SNDX) CEO Dr. Briggs Morrison on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/11/2021·↓ negative

Recap: Syndax Pharmaceuticals Q1 Earnings

Benzinga·5/11/2021·↑ positive

Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update

PRNewsWire·5/11/2021·↑ positive

Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021

PRNewsWire·5/4/2021·↑ positive

Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?

Zacks Investment Research·4/22/2021·↑ positive

Why Syndax Pharmaceuticals Stock Is Sinking Today

The Motley Fool·4/20/2021·↑ positive